V. Craig Jordan

V. Craig Jordan is recognized as the father of tamoxifen therapy for breast cancer, having established the scientific rationale for using selective estrogen receptor modulators (SERMs) in breast cancer treatment and prevention. His laboratory research defined the mechanisms by which tamoxifen acts as an ER antagonist in breast tissue while acting as an agonist in bone and uterus. He championed the use of tamoxifen in adjuvant therapy and prevention of breast cancer, leading to millions of women worldwide benefiting from the drug. His work on estrogen receptor biology continues to inform next-generation hormonal therapies.